Abstract：Objective：To observe the clinical efficacy of Weifuchun Capsules combined with Teprenone Capsules in treating chronic atrophic gastritis（CAG）. Methods： A total of 110 CAG patients treated at Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine from July 2021 to July 2024 were divided into the control group （55 cases，Teprenone Capsules）and the observation group（55 cases，Teprenone Capsules plus Weifuchun Capsules） using the random number table method. Clinical efficacy and incidence of adverse reactions， as well as traditional Chinese medicine syndrome scores，gastric mucosal pathology scores，serum gastrointestinal hormones [gastrin（GAS）， pepsinogenⅠ（PGⅠ），and pepsinogenⅡ（PGⅡ）]，and inflammatory factors [interleukin-8（IL-8），tumor necrosis factor-α（TNF-α）， and interleukin-6（IL-6）] were compared before and after treatment between the two groups. Results： The total effective rate in the observation group was 90.91%（50/55）， and that in the control group was 67.27%（37 / 55）， the difference being significant（P＜0.05）. After treatment， the traditional Chinese medicine syndrome scores of fatigue，stomach distension，epigastric pain，belching and acrid regurgitation and anorexia in the two groups decreased compared with those before treatment（P＜0.05），and the above five traditional Chinese medicine syndrome scores in the observation group were lower than those in the control group（P＜0.05）. After treatment， the pathological scores of chronic inflammatory reaction， atrophy， activity and intestinal metaplasia of gastric mucosa in the two groups decreased compared with those before treatment（P＜0.05），and the pathological scores of the above four items in the observation group were lower than those in the control group（P＜0.05）. After treatment，the levels of GAS in both groups decreased（P＜0.05）， and the levels of PG Ⅰ and PG Ⅱ increased（P＜0.05）compared with those before treatment. The GAS level in the observation group was lower than that in the control group（P＜0.05），and the levels of PG Ⅰ and PG Ⅱ in the observation group were higher than those in the control group（P＜0.05）. After treatment，the levels of IL-8，IL-6 and TNF-α in the two groups decreased compared with those before treatment（P＜ 0.05）， and the levels of the above three inflammatory factors in the observation group were lower than those in the control group（P＜0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（P＞0.05）. Conclusion： Weifuchun Capsules combined with Teprenone Capsules in treating CAG effectively improves gastric mucosal lesions and modulates levels of gastrointestinal hormones and inflammatory factors in patients.